"...drug did not meet its primary endpoint of progression-free survival compared to sorafenib in patients with metastatic renal cell carcinoma (mRCC) after failure with prior therapies."
Supposedly a trial in VEGFR TKI resistant patients, but as you can see below Dovi should be competitive with Sora. This could still be the case and the trial was stopped due to safety concern that Novartis will never disclose.
Dovitinib inhibits FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET similar to Pona's hit list, but at much higher IC50 values.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.